Antitrust Antitrust

Teva faces EU dominance probe over multiple sclerosis treatment

By Lewis Crofts
  • 06 Nov 2020 10:20
  • 06 Nov 2020 10:20
Teva was visited by EU antitrust officials in October 2019 as part of a probe into whether it had abused its market clout related to a treatment for multiple sclerosis, the pharmaceutical company has said.

In a filing to investors, Teva said it had also received follow-up questions from the European Commission and

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Lewis Crofts


Lewis leads MLex's editorial strategy, content direction, quality and development. He has a reputation for breaking stories and providing analysis on complex legal disputes before regulators and courts around the globe. He has also developed MLex's unrivalled coverage of competition policy, litigation, regulation, Brexit and international investigations.

Discover MLex

Stay on top of global regulatory developments

Latest News